Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Eitemau Tebyg

• Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
  gan: Leslie Amass, et al.
  Cyhoeddwyd: (2018-12-01)
• Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
  gan: Waddington Cruz, Márcia, et al.
  Cyhoeddwyd: (2016)
• Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
  gan: Keohane, Denis, et al.
  Cyhoeddwyd: (2015)
• Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
  gan: Waddington-Cruz, Marcia, et al.
  Cyhoeddwyd: (2015)
• Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
  gan: Gundapaneni, B. K., et al.
  Cyhoeddwyd: (2017)